Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

, BIIB

Biogen

$305.59

-0.4 (-0.13%)

07:22
10/10/16
10/10
07:22
10/10/16
07:22

Ionis drug likely to be approved rapidly, says Wells Fargo

After Ionis Pharmaceuticals (IONS) and partner Biogen (BIIB) reported detailed data for their RNA Therapeutic nusinersen, in patients with both symptomatic and pre-symptomatic type 1 Spinal Muscular Atrophy, as well as data for patients with type 2/3 Spinal Muscular Atrophy, or SMA, Wells Fargo says it expects the drug to be rapidly approved. The firm thinks that the FDA will approve "a broad label" covering pre-symptomatic and symptomatic type I SMA, as well as type 2/3 SMA. The firm says that the companies should have "a very large commercial opportunity," and it keeps an Outperform rating on Ionis.

IONS

Ionis Pharmaceuticals

BIIB

Biogen

$305.59

-0.4 (-0.13%)

  • 10

    Oct

  • 26

    Oct

  • 06

    Nov

IONS Ionis Pharmaceuticals

10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
10/06/16
RBCM
10/06/16
NO CHANGE
RBCM
Alnylam news not a negative read through on other RNAi drugs, says RBC Capital
After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, RBC Capital analyst Michael Yee does not thinks that the news indicates problems with all RNAi drugs. Rather, he thinks that RNAi was not the proper treatment for the disease that Alnylam was targeting. Other companies with RNAi treatments include The Medicines Company (MDCO0, Ionis Pharmaceuticals (IONS), Arrowhead (ARWR), and Arbutus Biopharma (ABUS).
10/06/16
WELS
10/06/16
NO CHANGE
WELS
Ionis has no read through from negative Alnylam data, says Wells Fargo
After Ionis (IONS) competitor Alnylam Pharmaceuticals (ALNY) announced that it was terminating the development of its revusiran RNAi drug due to poor outcomes in clinical trials, Wells Fargo thinks that the news is "a significant positive" for Ionis because it eliminates a competitor. The firm says that Ionis' drug is significantly different than Alnylam's product, and it believes that Ionis' treatment appears to be superior. The firm keeps an Outperform rating on Ionis.
10/06/16
BMOC
10/06/16
UPGRADE
BMOC
Outperform
Ionis Pharmaceuticals upgraded on reduced competition, valuation at BMO Capital
As noted earlier, BMO Capital upgraded Ionis (IONS) to Outperform from Market Perform. After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, BMO Capital analyst Do Kim expects Ionis to benefit from the reduced competition. Kim recommends buying Ionis' stock on weakness today. Target to $48 from $42.
BIIB Biogen
$305.59

-0.4 (-0.13%)

09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.
10/03/16
BMOC
10/03/16
NO CHANGE
Target $304
BMOC
Biogen potential trading opportunity into year-end, says BMO Capital
BMO Capital hosted a call with an expert on Alzheimers that may present a trading opportunity in Biogen (BIIB) shares as we approach sola Phase 3 and aducanumab titration data expected at year end. The expert said evidence supports the amyloid hypothesis of AD outweighs the evidence that undercuts it, but suggested that patient selection and trial design/execution key to demonstrating benefit to support regulatory approval. He estimated that Lilly's (LLY) EXPEDITION-3 trial has a ~60% probability of success, with Biogen's aducanumab greater than70% as long as rates of ARIA-E can be reduced with titration. Analyst Ian Somaiya believes positive Phase III Sola data could provide a positive read through to aducanumab and results in Biogen shares trading up 20-25%. If Sola misses, aducanumab's ability to clear beta amyloid oligomers & plaques and in our opinion a better trial design could limit downside in shares to approximately 10%. Somaiya rates Biogen a Market Perform with a $304 price target.
10/04/16
RBCM
10/04/16
NO CHANGE
Target $375
RBCM
Outperform
Biogen could rise $20 or more per share on SMA success, says RBC Capital
RBC Capital analyst Michael Yee expects the first presentation of data from Biogen's (BIIB) Phase III ENDEAR trial studying nusinersen, an investigational treatment for spinal muscular atrophy, or SMA, this week, potentially during the late breaker session at the WMS Congress on October 8. Biogen and partner Ionis Pharmaceuticals (IONS) already announced in August that the study in Type I infants hit the interim analysis and stopped early for positive data. The much larger opportunity in older children has data expected to read out in Spring 2017, noted Yee, who thinks Biogen can have upside from $10 to over $20 per share based on its SMA opportunity. Yee keeps an Outperform rating and $375 price target on Biogen shares.

TODAY'S FREE FLY STORIES

XPER

Xperi

$22.50

-0.25 (-1.10%)

09:01
01/23/18
01/23
09:01
01/23/18
09:01
Hot Stocks
Xperi partners with ARCloud to bring music recognition to hybrid ratio »

Xperi Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:00
01/23/18
01/23
09:00
01/23/18
09:00
General news
U.S. equities are relatively subdued »

U.S. equities are…

FQVLF

First Quantum Minerals

$15.30

-0.01 (-0.07%)

08:59
01/23/18
01/23
08:59
01/23/18
08:59
Downgrade
First Quantum Minerals rating change  »

First Quantum Minerals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$53.46

1.55 (2.99%)

08:59
01/23/18
01/23
08:59
01/23/18
08:59
Hot Stocks
Verizon says not considering large media acquisition »

Says remaining a partner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

SANM

Sanmina

$27.08

-8.35 (-23.57%)

08:59
01/23/18
01/23
08:59
01/23/18
08:59
Recommendations
Sanmina analyst commentary  »

Sanmina price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

JMBA

Jamba

08:59
01/23/18
01/23
08:59
01/23/18
08:59
Technical Analysis
Technical Take: Jamba down sharply on 2.1M share Block Trade »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TWTR

Twitter

$23.34

-0.31 (-1.31%)

08:57
01/23/18
01/23
08:57
01/23/18
08:57
Hot Stocks
Twitter COO Anthony Noto resigns to accept CEO role at other company »

Twitter announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

08:57
01/23/18
01/23
08:57
01/23/18
08:57
General news
Redbook Store Sales data reported »

Week of 1/20 Redbook…

SANM

Sanmina

$27.10

-8.35 (-23.55%)

08:56
01/23/18
01/23
08:56
01/23/18
08:56
Recommendations
Sanmina analyst commentary  »

Sanmina price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

WWD

Woodward

$81.02

0.52 (0.65%)

08:56
01/23/18
01/23
08:56
01/23/18
08:56
Initiation
Woodward initiated  »

Woodward re-initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

TWTR

Twitter

$23.32

-0.34 (-1.44%)

08:55
01/23/18
01/23
08:55
01/23/18
08:55
Hot Stocks
Breaking Hot Stocks news story on Twitter »

Twitter announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

GE

General Electric

$16.17

-0.09 (-0.55%)

, NFLX

Netflix

$227.58

7.12 (3.23%)

08:55
01/23/18
01/23
08:55
01/23/18
08:55
Options
Notable open interest changes for January 23rd »

Monday's total…

GE

General Electric

$16.17

-0.09 (-0.55%)

NFLX

Netflix

$227.58

7.12 (3.23%)

AAPL

Apple

$177.00

-1.46 (-0.82%)

BAC

Bank of America

$31.94

0.22 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 30

    Jan

  • 01

    Feb

  • 15

    Feb

JMBA

Jamba

$9.14

-0.01 (-0.11%)

08:54
01/23/18
01/23
08:54
01/23/18
08:54
Syndicate
Jamba 2.1M share Block Trade priced at $8.25 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ANET

Arista Networks

$275.68

4.84 (1.79%)

08:54
01/23/18
01/23
08:54
01/23/18
08:54
Recommendations
Arista Networks analyst commentary  »

Arista Networks price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 21

    Feb

  • 26

    Feb

  • 13

    Mar

  • 14

    Mar

FSLR

First Solar

$68.96

-1.07 (-1.53%)

, TSLA

Tesla

$351.56

1.54 (0.44%)

08:53
01/23/18
01/23
08:53
01/23/18
08:53
Recommendations
First Solar, Tesla, JinkoSolar, JA Solar, Sunrun, Vivint Solar analyst commentary  »

30% solar import tariff…

FSLR

First Solar

$68.96

-1.07 (-1.53%)

TSLA

Tesla

$351.56

1.54 (0.44%)

JKS

JinkoSolar

$23.37

-0.8 (-3.31%)

JASO

JA Solar

$7.46

-0.01 (-0.13%)

RUN

Sunrun

$6.04

0.1 (1.68%)

VSLR

Vivint Solar

$3.55

-0.15 (-4.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$53.46

1.55 (2.99%)

08:52
01/23/18
01/23
08:52
01/23/18
08:52
Hot Stocks
Breaking Hot Stocks news story on Verizon »

Verizon says integration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

JWN

Nordstrom

$52.82

0.82 (1.58%)

08:52
01/23/18
01/23
08:52
01/23/18
08:52
Downgrade
Nordstrom rating change  »

William Blair downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LITE

Lumentum

$45.20

-3.65 (-7.47%)

08:51
01/23/18
01/23
08:51
01/23/18
08:51
Recommendations
Lumentum analyst commentary  »

Lumentum price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

NDAQ

Nasdaq

$80.63

0.56 (0.70%)

, CBOE

Cboe Global Markets

$134.56

0.68 (0.51%)

08:49
01/23/18
01/23
08:49
01/23/18
08:49
Periodicals
Nasdaq assessing bitcoin futures that are different to rivals, CNBC reports »

Nasdaq (NDAQ) is…

NDAQ

Nasdaq

$80.63

0.56 (0.70%)

CBOE

Cboe Global Markets

$134.56

0.68 (0.51%)

CME

CME Group

$155.45

1.17 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 01

    Feb

  • 09

    Feb

LOGI

Logitech

$37.58

0.25 (0.67%)

08:49
01/23/18
01/23
08:49
01/23/18
08:49
Technical Analysis
Technical Take: Logitech up sharply after results beat consensus, FY18 view »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

RMD

ResMed

$87.51

-1.17 (-1.32%)

08:49
01/23/18
01/23
08:49
01/23/18
08:49
Upgrade
ResMed rating change  »

ResMed upgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GGAL

Grupo Financiero

$69.79

-2.27 (-3.15%)

08:48
01/23/18
01/23
08:48
01/23/18
08:48
Initiation
Grupo Financiero initiated  »

Grupo Financiero…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$53.46

1.55 (2.99%)

08:48
01/23/18
01/23
08:48
01/23/18
08:48
Hot Stocks
Verizon says seeing elongation of upgrade cycle »

Says customers keeping…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

TRV

Travelers

$139.35

1.5 (1.09%)

08:47
01/23/18
01/23
08:47
01/23/18
08:47
Technical Analysis
Technical Take: Travelers trades at new high after earnings beat »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

JNJ

Johnson & Johnson

$148.14

0.78 (0.53%)

08:46
01/23/18
01/23
08:46
01/23/18
08:46
Hot Stocks
Johnson & Johnson 'very pleased' with launch of Tremfya »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.